Psychopharmacology

, Volume 208, Issue 3, pp 417–426 | Cite as

Neuropeptide Y (NPY) suppresses yohimbine-induced reinstatement of alcohol seeking

  • Andrea Cippitelli
  • Ruslan Damadzic
  • Anita C. Hansson
  • Erick Singley
  • Wolfgang H. Sommer
  • Robert Eskay
  • Annika Thorsell
  • Markus Heilig
Original Investigation

Abstract

Introduction

Reinstatement of responding to a previously alcohol-associated lever following extinction is an established model of relapse-like behavior and can be triggered by stress exposure. Here, we examined whether neuropeptide Y (NPY), an endogenous anti-stress mediator, blocks reinstatement of alcohol-seeking induced by the pharmacological stressor yohimbine.

Materials and methods

NPY [5.0 or 10.0 μg/rat, intracerebroventricularly (ICV)] dose-dependently blocked the reinstatement of alcohol seeking induced by yohimbine (1.25 mg/kg, i.p.) but failed to significantly suppress the maintenance of alcohol self-administration. We then used c-fos expression mapping to examine neuronal activation following treatment with yohimbine or NPY alone or yohimbine following NPY pre-treatment.

Results and discussion

The analysis was focused on a network of structures previously implicated in yohimbine-induced reinstatement, comprised of central (CeA) and basolateral (BLA) amygdala and the shell of the nucleus accumbens (Nc AccS). Within this network, both yohimbine and NPY potently induced neuronal activation, and their effects were additive, presumably indicating activation of excitatory and inhibitory neuronal populations, respectively.

Conclusion

These results suggest that NPY selectively suppresses relapse to alcohol seeking induced by stressful events and support the NPY system as an attractive target for the treatment of alcohol addiction.

Keywords

Yohimbine Reinstatement Alcohol seeking c-fos NPY Relapse 

References

  1. Aghajanian GK, Vandermaelen CP (1982) alpha 2-adrenoceptor-mediated hyperpolarization of locus coeruleus neurons: intracellular studies in vivo. Science 215:1394–1396CrossRefPubMedGoogle Scholar
  2. Albers HE, Ottenweller JE, Liou SY, Lumpkin MD, Anderson ER (1990) Neuropeptide Y in the hypothalamus: effect on corticosterone and single-unit activity. Am J Physiol 258:R376–R382PubMedGoogle Scholar
  3. Badia-Elder NE, Stewart RB, Powrozek TA, Roy KF, Murphy JM, Li TK (2001) Effect of neuropeptide Y (NPY) on oral ethanol intake in Wistar, alcohol-preferring (P), and -nonpreferring (NP) rats. Alcohol Clin Exp Res 25:386–390CrossRefPubMedGoogle Scholar
  4. Badia-Elder NE, Stewart RB, Powrozek TA, Murphy JM, Li TK (2003) Effects of neuropeptide Y on sucrose and ethanol intake and on anxiety-like behavior in high alcohol drinking (HAD) and low alcohol drinking (LAD) rats. Alcohol Clin Exp Res 27:894–899PubMedGoogle Scholar
  5. Banihashemi L, Rinaman L (2006) Noradrenergic inputs to the bed nucleus of the stria terminalis and paraventricular nucleus of the hypothalamus underlie hypothalamic–pituitary–adrenal axis but not hypophagic or conditioned avoidance responses to systemic yohimbine. J Neurosci 26:11442–11453CrossRefPubMedGoogle Scholar
  6. Beck CH, Fibiger HC (1995) Conditioned fear-induced changes in behavior and in the expression of the immediate early gene c-fos: with and without diazepam pretreatment. J Neurosci 15:709–720PubMedGoogle Scholar
  7. Carvajal C, Dumont Y, Quirion R (2006) Neuropeptide y: role in emotion and alcohol dependence. CNS Neurol Disord Drug Targets 5:181–195CrossRefPubMedGoogle Scholar
  8. Charney DS, Heninger GR, Redmond DE Jr (1983) Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci 33:19–29CrossRefPubMedGoogle Scholar
  9. Charney DS, Woods SW, Heninger GR (1989) Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res 27:173–182CrossRefPubMedGoogle Scholar
  10. Cippitelli A, Cannella N, Braconi S, Duranti A, Tontini A, Bilbao A, Defonseca FR, Piomelli D, Ciccocioppo R (2008) Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. Psychopharmacology (Berl) 198:449–460CrossRefGoogle Scholar
  11. Deak T, Nguyen KT, Ehrlich AL, Watkins LR, Spencer RL, Maier SF, Licinio J, Wong ML, Chrousos GP, Webster E, Gold PW (1999) The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140:79–86CrossRefPubMedGoogle Scholar
  12. Funk D, Li Z, Le AD (2006) Effects of environmental and pharmacological stressors on c-fos and corticotropin-releasing factor mRNA in rat brain: relationship to the reinstatement of alcohol seeking. Neuroscience 138:235–243CrossRefPubMedGoogle Scholar
  13. Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF (2007) Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry 61:78–86CrossRefPubMedGoogle Scholar
  14. Gehlert DR, Cippitelli A, Thorsell A, Le AD, Hipskind PA, Hamdouchi C, Lu J, Hembre EJ, Cramer J, Song M, McKinzie D, Morin M, Ciccocioppo R, Heilig M (2007) 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2, 6-dimethyl- imidazo[1, 2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci 27:2718–2726CrossRefPubMedGoogle Scholar
  15. Gilpin NW, Misra K, Koob GF (2008) Neuropeptide Y in the central nucleus of the amygdala suppresses dependence-induced increases in alcohol drinking. Pharmacol Biochem Behav 90:475–480CrossRefPubMedGoogle Scholar
  16. Hansson AC, Cippitelli A, Sommer WH, Fedeli A, Bjork K, Soverchia L, Terasmaa A, Massi M, Heilig M, Ciccocioppo R (2006) Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. Proc Natl Acad Sci USA 103:15236–15241CrossRefPubMedGoogle Scholar
  17. Hansson AC, Rimondini R, Neznanova O, Sommer WH, Heilig M (2008) Neuroplasticity in brain reward circuitry following a history of ethanol dependence. Eur J Neurosci 27:1912–1922CrossRefPubMedGoogle Scholar
  18. Heilig M, Koob GF (2007) A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 30:399–406CrossRefPubMedGoogle Scholar
  19. Heilig M, Soderpalm B, Engel JA, Widerlov E (1989) Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 98:524–529CrossRefGoogle Scholar
  20. Heilig M, McLeod S, Brot M, Heinrichs SC, Menzaghi F, Koob GF, Britton KT (1993) Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 8:357–363PubMedGoogle Scholar
  21. Heilig M, Koob GF, Ekman R, Britton KT (1994) Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci 17:80–85CrossRefPubMedGoogle Scholar
  22. Heimer L (2003) A new anatomical framework for neuropsychiatric disorders and drug abuse. Am J Psychiatry 160:1726–1739CrossRefPubMedGoogle Scholar
  23. Heimer L, Van Hoesen GW (2006) The limbic lobe and its output channels: implications for emotional functions and adaptive behavior. Neurosci Biobehav Rev 30:126–147CrossRefPubMedGoogle Scholar
  24. Koob GF (2009) Brain stress systems in the amygdala and addiction. Brain Res 1293:61–75CrossRefPubMedGoogle Scholar
  25. Krysiak R, Obuchowicz E, Herman ZS (1999) Interactions between the neuropeptide Y system and the hypothalamic–pituitary–adrenal axis. Eur J Endocrinol 140:130–136CrossRefPubMedGoogle Scholar
  26. Le AD, Quan B, Juzytch W, Fletcher PJ, Joharchi N, Shaham Y (1998) Reinstatement of alcohol-seeking by priming injections of alcohol and exposure to stress in rats. Psychopharmacology (Berl) 135:169–174CrossRefGoogle Scholar
  27. Le AD, Harding S, Juzytsch W, Watchus J, Shalev U, Shaham Y (2000) The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology (Berl) 150:317–324CrossRefGoogle Scholar
  28. Le AD, Harding S, Juzytsch W, Funk D, Shaham Y (2005) Role of alpha-2 adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats. Psychopharmacology (Berl) 179:366–373CrossRefGoogle Scholar
  29. Liu X, Weiss F (2002) Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci 22:7856–7861PubMedGoogle Scholar
  30. Marinelli PW, Funk D, Juzytsch W, Harding S, Rice KC, Shaham Y, Le AD (2007) The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berl) 195:345–355CrossRefGoogle Scholar
  31. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, San DiegoGoogle Scholar
  32. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic, San DiegoGoogle Scholar
  33. Rassnick S, Heinrichs SC, Britton KT, Koob GF (1993) Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 605:25–32CrossRefPubMedGoogle Scholar
  34. Rimondini R, Thorsell A, Heilig M (2005) Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in rats with a history of dependence. Neurosci Lett 375:129–133CrossRefPubMedGoogle Scholar
  35. Sajdyk TJ, Shekhar A, Gehlert DR (2004) Interactions between NPY and CRF in the amygdala to regulate emotionality. Neuropeptides 38:225–234CrossRefPubMedGoogle Scholar
  36. Salminen O, Lahtinen S, Ahtee L (1996) Expression of Fos protein in various rat brain areas following acute nicotine and diazepam. Pharmacol Biochem Behav 54:241–248CrossRefPubMedGoogle Scholar
  37. Shaham Y, Shalev U, Lu L, de Wit H, Stewart J (2003) The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168:3–20CrossRefGoogle Scholar
  38. Shepard JD, Bossert JM, Liu SY, Shaham Y (2004) The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse. Biol Psychiatry 55:1082–1089CrossRefPubMedGoogle Scholar
  39. Singewald N, Salchner P, Sharp T (2003) Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol Psychiatry 53:275–283CrossRefPubMedGoogle Scholar
  40. Suda T, Tozawa F, Iwai I, Sato Y, Sumitomo T, Nakano Y, Yamada M, Demura H (1993) Neuropeptide Y increases the corticotropin-releasing factor messenger ribonucleic acid level in the rat hypothalamus. Brain Res Mol Brain Res 18:311–315CrossRefPubMedGoogle Scholar
  41. Thiele TE, Marsh DJ, Ste M, Bernstein IL, Palmiter RD (1998) Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature 396:366–369CrossRefPubMedGoogle Scholar
  42. Thiele TE, Koh MT, Pedrazzini T (2002) Voluntary alcohol consumption is controlled via the neuropeptide Y Y1 receptor. J Neurosci 22:RC208PubMedGoogle Scholar
  43. Thiele TE, Sparta DR, Hayes DM, Fee JR (2004) A role for neuropeptide Y in neurobiological responses to ethanol and drugs of abuse. Neuropeptides 38:235–243CrossRefPubMedGoogle Scholar
  44. Thompson BL, Rosen JB (2006) Immediate-early gene expression in the central nucleus of the amygdala is not specific for anxiolytic or anxiogenic drugs. Neuropharmacology 50:57–68CrossRefPubMedGoogle Scholar
  45. Thorsell A (2007) Neuropeptide Y (NPY) in alcohol intake and dependence. Peptides 28:480–483CrossRefPubMedGoogle Scholar
  46. Thorsell A, Rimondini R, Heilig M (2002) Blockade of central neuropeptide Y (NPY) Y2 receptors reduces ethanol self-administration in rats. Neurosci Lett 332:1–4CrossRefPubMedGoogle Scholar
  47. Thorsell A, Slawecki CJ, Ehlers CL (2005a) Effects of neuropeptide Y and corticotropin-releasing factor on ethanol intake in Wistar rats: interaction with chronic ethanol exposure. Behav Brain Res 161:133–140CrossRefPubMedGoogle Scholar
  48. Thorsell A, Slawecki CJ, Ehlers CL (2005b) Effects of neuropeptide Y on appetitive and consummatory behaviors associated with alcohol drinking in wistar rats with a history of ethanol exposure. Alcohol Clin Exp Res 29:584–590CrossRefPubMedGoogle Scholar
  49. Thorsell A, Repunte-Canonigo V, O’Dell LE, Chen SA, King AR, Lekic D, Koob GF, Sanna PP (2007) Viral vector-induced amygdala NPY overexpression reverses increased alcohol intake caused by repeated deprivations in Wistar rats. Brain 130:1330–1337CrossRefPubMedGoogle Scholar
  50. Tsagarakis S, Rees LH, Besser GM, Grossman A (1989) Neuropeptide-Y stimulates CRF-41 release from rat hypothalami in vitro. Brain Res 502:167–170CrossRefPubMedGoogle Scholar
  51. Tsujino T, Sano H, Kubota Y, Hsieh ST, Miyajima T, Saito K, Nakajima M, Saito N, Yokoyama M (1992) Expression of Fos-like immunoreactivity by yohimbine and clonidine in the rat brain. Eur J Pharmacol 226:69–78CrossRefPubMedGoogle Scholar
  52. Valdez GR, Koob GF (2004) Allostasis and dysregulation of corticotropin-releasing factor and neuropeptide Y systems: implications for the development of alcoholism. Pharmacol Biochem Behav 79:671–689CrossRefPubMedGoogle Scholar
  53. Weiss F, Lorang MT, Bloom FE, Koob GF (1993) Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J Pharmacol Exp Ther 267:250–258PubMedGoogle Scholar

Copyright information

© US Government 2009

Authors and Affiliations

  • Andrea Cippitelli
    • 1
  • Ruslan Damadzic
    • 1
  • Anita C. Hansson
    • 1
    • 2
  • Erick Singley
    • 1
  • Wolfgang H. Sommer
    • 1
    • 2
  • Robert Eskay
    • 1
  • Annika Thorsell
    • 1
  • Markus Heilig
    • 1
  1. 1.Laboratory of Clinical and Translational Studies, National Institute of Alcohol Abuse and Alcoholism (NIAAA)National Institutes of Health (NIH)BethesdaUSA
  2. 2.Department of PsychopharmacologyUniversity of HeidelbergMannheimGermany

Personalised recommendations